Word: merck
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...debate begins in earnest this week, when the FDA conducts hearings on requests by Merck & Co., maker of Mevacor, and Bristol-Myers Squibb Co., manufacturer of Pravachol, to sell lower-dose versions of their cholesterol-lowering products over the counter (OTC). If the FDA approves the switch, it may unleash a flood of similar requests from other drugmakers...
...Merck and Bristol-Myers Squibb say they are pushing for OTC status for their products to make them more widely and cheaply available. But analysts note that Merck's patent on Mevacor expires next year. And while Bristol-Myers Squibb's patent on Pravachol runs to 2005, generic versions of Mevacor will surely cut into Pravachol's sales, justifying Bristol-Myers' push for OTC too. An added benefit: a switch could give the maker exclusive selling rights on the drug for three more years. That's why medicines like the hair-loss treatment Rogaine (owned by Pharmacia Corp...
...cure you. It is also unlike pretty much every other illicit drug. Ecstasy pills are (or at least they are supposed to be) made of a compound called methylenedioxymethamphetamine, or MDMA. It's an old drug: Germany issued the patent for it in 1914 to the German company E. Merck. Contrary to ecstasy lore, and there's tons of it, Merck wasn't trying to develop a diet drug when it synthesized MDMA. Instead, its chemists simply thought it could be a promising intermediary substance that might be used to help develop more advanced therapeutic drugs. There's also...
...motivated as much by enlightened self-interest as by altruism, but the decision by five pharmaceutical giants to slash the price of AIDS drugs in Africa has the potential to be an important milestone in the battle against the killer disease. Bristol Myers Squibb, Glaxo Wellcome PLC, Merck and Co., Boehringer Ingelheim GmbH and Roche Holding AG are set Thursday to announce a program negotiated with the United Nations to cut the price of AIDS drugs by as much as 90 percent on a continent where more than 23 million people are infected with HIV. The business context for that...
Some of the most promising natural wonder drugs come from compounds not usually associated with healing: poisons. Merck is marketing a blood thinner based on the venom of the deadly saw-scaled viper. A protein from another Asian pit viper is being studied because it appears to inhibit the spread of melanoma cells, and a compound called SNX-482 from the venom of the Cameroon red tarantula may lead to new treatments for neurological disorders...